Stay updated on Helix BioPharma Press Releases
Sign up to get notified when there's something new on the Helix BioPharma Press Releases page.

Latest updates to the Helix BioPharma Press Releases page
- CheckyesterdayChange DetectedA new news item dated 30 Jun 2026 about strengthening executive leadership to support the U.S. listing strategy and clinical development was added to the News & Media Releases. The entry for 29 Oct 2025, Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results, was removed from the listings.SummaryDifference2%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedA new news entry dated 12 Jun 2026 has been added to the News & Media Releases section, announcing financial results and interim financial statements for the three- and nine-month period ended April 30, 2026, and it includes the company address.SummaryDifference2%

- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedA new news entry dated 03 Jun 2026 was added announcing the closing of a private placement of convertible debentures. An older post from 09 Sep 2025, the 'Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025' post, and the Pipeline navigation item were removed from the News section.SummaryDifference2%

- Check37 days agoChange DetectedA new News item dated 22 May 2026 reports the grant and cancellation of stock options, reflecting ongoing governance and compensation updates. A previous press release dated 05 Sep 2025 about not proceeding with an equity draw-down facility has been removed from the listings, altering the historical financing context on the News page.SummaryDifference2%

- Check51 days agoChange DetectedAdds a new news item dated 13 May 2026 announcing strategic board and governance appointments to support financing and Nasdaq uplisting strategy. Removes the August 22, 2025 item regarding the closing of a private placement in preparation for institutional investment and Nasdaq uplisting.SummaryDifference2%

- Check108 days agoChange DetectedAdded a new news item: Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026. Removed the 2025 Frontiers in Oncology publication on the Effects of L-DOS47 as Monotherapy in NSCLC.SummaryDifference2%

Stay in the know with updates to Helix BioPharma Press Releases
Enter your email address, and we'll notify you when there's something new on the Helix BioPharma Press Releases page.